Background:
Summary
Background: l3l I-meta-iodobenzylguanidine (MIBG) has been used with success for the palliation of metastatic carcinoid. To qualify more patients for this treatment, we evaluated the effect of predosing with non-radiolabeled MIBG on 
Results:
In six patients, highly increased 'tumour/nontumour' ratios were seen due to reduced levels in normal tissues and increased tumour accumulation. The combined treatment applied in five patients, considerably improved symptoms in all (duration 6-12 months), accompanied by biochemical response in three. In BON carcinoid xenografted mice, MIBG was injected intraperitoneally followed by intravenous 125 
Introduction
Carcinoid tumours belong to the group of neuroendocrine tumours and are well known for their symptoms of flushes and diarrhoea if they produce peptide hormones. The primary tumour is often localised in the mid-gut, especially the small bowel. Even in the presence of extensive liver metastases prognosis is relatively good, with a median survival of 53 months [1] . Treatment with the somatostatin analogue octreotide or interferon-a is well known and primarily aimed at long term palliation of the incapacitating symptoms. Amelioration of symptoms occurs in 60%-80% and a biochemical response in 40%-70% of patients, whereas tumour reduction is only occasionally reported [1] .
A completely different approach is the application of MIBG (meta-iodobenzylguanidine). When radiolabeled with a tracer dose of 370 MBq (10 mCi) I23 I-MIBG or 37 MBq (1 mCi) 131 I-MIBG, it has been applied for tumour imaging. After crossing the cell membrane, MIBG is subsequently stored in the neurosecretory granules of neuroendocrine cells being responsible for a positive MIBG scan in 70% of the carcinoid patients [2, 3] . If sufficient MIBG accumulates in the tumour sites compared to normal tissues, the tumour can be locally irradiated using a high therapeutic dose of 7.4 GBq (=200 mCi) I3I I-MIBG. As previously described, a clear symptomatic improvement was found in 60% of usually pretreated carcinoid patients following two cycles of I31 I-MIBG [4] . Although a biochemical response occurred in only 7%, the main advantage of this treatment is the long lasting palliative effect, with a median of eight months, at the cost of minimal side effects. Targeted radiotherapy is not an option in patients with a negative or weakly positive 13I I-MIBG scintigram. Notably, in such patients a similar beneficial effect has been found with the non-radiolabeled MIBG compound in pharmacological doses (10-40 mg/m 2 ), although this was of shorter duration, i.e., 4-5 months, than after 13I I-MIBG radiotherapy [4] . Based upon a previous observation [4, 5] that 13I I-MIBG scintigraphy immediately following infusion of a pharmacological dose of non-radiolabeled MIBG revealed increased tumour/non-tumour ratios in a patient who showed no or little uptake on the pretreatment scintigraphy, we further exploited this treatment modification. In the present study we have evaluated the effect of predosing with an excess of MIBG on the biodistribution of a subsequently administered I3I I-MIBG tracer dose in 10 carcinoid patients with a negative I31 I-MIBG scan, wich is approximately 30% of all carcinoid patients seen in our hospital [2] . This favourably affected the biodistribution, i.e., less background radioactivity and often improved tumour targeting, in such a way that five patients were also treated with a high radioactivity dose of l31 I-MIBG after predosing with non-radiolabeled MIBG. To better understand the 131 I-MIBG targeting in carcinoids we have also investigated the effect of predosing in a xenograft model of nude mice with BON human carcinoid tumours [6] .
Patients and methods

Patients and
I31
I-MIBG scintigrapby
Between 1994 and 1997 10 carcinoid patients (2 men and 8 women) with symptoms of flushes and diarrhoea due to overproduction of serotonin, measured as elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion, or elevated serum levels of VIP (vasoactive intestinal peptide) in one case ( Because the retention of the radioactive tracer dose was not sufficient to qualify for the therapeutic dose of 131 I-M1BG in these 10 patients, they were treated with a pharmacological dose of the nonradiolabeled MIBG (MIBG.1/2H 2 SO 4 ; EMKA Chemie, Neufahrn, Germany) as reported earlier [4] . A total of three courses were applied in increasing doses of 10, 20 and 40 mg/m 2 per patient by intravenous infusion over four hours at four-week intervals. The second course of 20 mg/m 2 was immediately followed by slow intravenous injection of a tracer dose 37 MBq 131 I-MIBG (1 mCi; containing 1 mg of MIBG) for scintigraphy. Total body imaging was performed after 24, 48 and 72 hours using a dual head large field-of-view gamma camera (ADAC Dual Genesys or Vertex) with high energy general purpose (HEPG) collimators, connected with a network of computer work stations (ADAC Pegasys). Multiple planar images with an acquisition time of 10 minutes in a 256 x 256 matrix were made of the whole body.
The scintigrams obtained after treatment with non-radiolabeled MIBG were compared to the pretreatment scans. The normal tissue distribution of I31 I-MIBG and its tumour/non-tumour ratios were analysed. The difference in MIBG accumulation in the salivary glands, myocardium, liver and lungs was scored visually: = means no difference, < minimal decrease, < decrease, << marked decrease, -no uptake, > minimal increase, > increase, and >> marked increase. The tumour/non-tumour ratios were determined both by a similar visual scoring system (++ means a clear improvement with increased retention in the tumour and less background uptake, + improvement, = /+ minimal improvement, = no change, deterioration with less retention in the tumour) and quantitatively. Whenever 13I I-MIBG was given, either as a tracer dose or a treatment dose, the patients received oral potassium iodide, 200 mg daily for five days, starting one day before the 13I I-MIBG to avoid radioactive iodide uptake by the thyroid.
Subjective improvement was considered as a partial remission (PR) in the case of a 50% decrease in stool frequency and/or a reduction of medication (e.g., loperamide) by > 50%. Biochemical PR was defined as a > 50% reduction of urinary 5-HIAA excretion.
Combined MIBG treatment
In those patients in which predosing with non-radiolabeled MIBG resulted in a clearly improved tumour targeting and hence a positive I3I I-MIBG scintigram, the combined treatment was applied. Nonradiolabeled MIBG (dose 20 or 40 mg/m 2 ) was administered by intravenous infusion over four hours, during which the blood pressure was measured every 30 minutes. If no side effects were encountered, treatment was immediately followed by four-hour infusion of 7.4 GBq '•"i-MIBG (200 mCi; containing 5 mg MIBG). Patients were isolated from the start of the infusion with the radiopharmaceutical according to legislation, in the Netherlands usually five to seven days. The patients received a total of two cycles with a six-to eight-week interval (Table 2) .
' 2 5 I -M I B G biodlstrlbution studies in carcinoid xenografted mice
Human pancreatic carcinoid BON cells (donated by Dr B. M. Evers, Department of Surgery, University of Texas Medical Branche, Galvestone, Texas) were cultured in vitro [6] , Female athymic BALB/c nulnu mice were obtained from the specific pathogen-free breeding unit of our animal facility. Experiments were performed in accordance with the national regulations for animal experiments and protocols were approved by the local animal welfare committee. Carcinoid xenografts were induced by s.c. injection of 2 x 10 6 freshly harvested BON cells at the flank of nude mice (age 5-6 weeks). After 12 days, the MIBG predosing experiment was started when tumours were exponentially growing with tumour volume doubling times of 3-3.5 days.
Five minutes after intraperitoneal injection of 0.1 mg MIBG (in 0.4 ml) or phosphate-buffered saline (PBS) for the controls, mice received an i.v. injection of 0.75 MBq 125 I-MIBG (specific activity 810-918 MBq/mg) in 200 ul PBS. Reported doses are for 20 g body weight and were adjusted proportionally to individual body weights (mean + SD: 19.1 ± 1.7, n = 8). After 24 hours, mice were bled by the carotid artery under ether anaesthesia and sacrificed. The tumours (mean ± SD: 66 ± 25 mg, n = 8) and tissues of interest were excised, weighed and gamma counted to determine the radioactivity levels. These were expressed as percentage of the injected radioactivity dose per gram tissue or per ml blood.
Results
Clinical studies
In 10 carcinoid patients (median age 61 years, range 38-83) with a weakly positive I31 I-MIBG scan, the scintigraphy was repeated after pretreatment with the nonradiolabeled MIBG in a dose of 20 mg/m 2 . As shown in Table 1 , all patients suffered from liver metastases and the carcinoid syndrome with the need for hospitalisation in six of them. In all, except one patient with a VIPoma (no. 9), the urinary 5-HIAA excretion was clearly elevated at the start of this study. Six patients showed progressive disease, while on octreotide treatment, which was continued during the study. Four patients had not yet received specific treatment. Compared to the initial scintigraphy the I31 I-MIBG retention after predosing with non-radiolabeled MIBG (Table 1) showed mainly a diminished uptake in normal tissues: especially in the salivary glands (9 of 10), the heart (8 of 10), and the remaining normal parts of the liver (6 of 10). In contrast, uptake in the lung was occasionally increased (3 of 10). Retention in the liver metastases was more pronounced in six patients (nos 1-6), including 3 (nos 1-3) with considerable improvement (Figures 1-4) . Reduced background radioactivity alone resulted also in an improved tumour/non-tumour ratio in patient seven and eight. As accumulation of 131 I-MIBG in the metastatic sites of the liver remained unchanged these patients were no candidate for the combined treatment.
Based on this favourably altered biodistribution, treatment with the high radioactivity dose of was considered feasible in patients 1-6 using the MIBG predosing protocol (Table 1) . However, in one patient of old age (83 years), the poor general condition prohibited the isolation procedure requiring a fair degree of selfcare for 5-7 days. The five patients who received the combined regimen (Table 2) , experienced all a symptomatic improvement: a 50% reduction in either stool frequency or in the need for additional medication, for example loperamide. The palliative effect was accompanied by a decrease in urinary 5-HIAA excretion, in three of them meeting the criteria of partial response (>50% decrease). The duration of response was remarkably Figure I . A young woman (patient no. 3) presented with the carcinoid syndrome (flushes and mild diarrhoea) and a clearly enlarged liver due to wide spread liver metastases at the CT-scan; the primary tumour remained unkown.
long lasting with a median of 11 months (range 6-12 months). In one patient (no. 3) a single combined cycle after one year, again induced a symptomatic improvement for seven months and a clear fall in 5-HIAA excretion. Data of the 5-HIAA excretion of the first treatment regimen are not available in this particular patient, because the 24 hours urine was accidently lost for analysis. In case of progression, subsequent treatment with the more or less standard treatment of octreotide (2-3x 100 ug s.c. daily) was effective in terms of symptomatic relief, but not always accompanied by biochemical remission ( Table 2 ). The overall survival was relatively long. One patient died (no. 1) after 79 months due to heart failure in the presence of severe tricuspid valve insufficiency; another (no. 4) patient died after 37 months due to meningeal and brain metastases. Side effects of the combined treatment were mild and of short duration, starting the day after the treatment with less appetite and some nausea occasionally requiring metoclopramide, and lasting for two or three days at the most. Bone marrow depression, liver or renal function disturbances did not occur. The isolation procedure was well tolerated. Late side effects did not occur.
[-MIBG biodistribution studies in carcinoid xenografted mice
To indicate the biological relevance of the BON human carcinoid xenograft model for MIBG targeting studies, we have compared these s.c. tumours with the well characterized s.c. SK-N-SH neuroblastoma xenografts [7] . Pharmacokinetic experiments demonstrated that the grafts was nearly as high as that of the neuro-blastoma tumours. The average BON tumour radioactivity levels decreased from 1.1 ± 0.4 to 0.3 ± 0.05% injected dose per gram (mean ± SD, n -3-5) between 3.5 and 93 hours after tracer I25 I-MIBG injection, with 'tumour over plasma' ratios increasing from 2 to 70 over the same period. The radiopharmaceutical disappeared slowly from the s.c. BON xenografts with an estimated biological T1/2 value of 48 hours.
Subsequently, the effect of an excess of non-radiolabeled MIBG (5 mg per kg) on the tissue distribution prior to a 125 I-MIBG tracer dose was evaluated. The radioactivity levels of the normal tissues were significantly reduced by at least a factor two. However, the I25 I-MIBG level remained unchanged in the BON tumour ( Figure 5) . Consequently, the 'BON tumour over normal tissue' ratio of 125 I-MIBG shifted from less than 1 to 1.5-3.0, demonstrating a more selective tumour targeting.
Discussion
From 1984 onwards 13I I-MIBG retention in neurosecretory granules of carcinoid tumour cells has been applied as a diagnostic tool [8] resulting in a sensitivity of 70% [2, 9] . Subsequently, a higher radioactivity dose resulted by its internal irradiation in longterm palliation in 60% of patients with advanced carcinoid disease [4] . The present study shows that treatment modification by predosing with non-radiolabeled MIBG can result in an improved tumour targeting in carcinoid patients. At diagnostic imaging the biodistribution of 131 I-MIBG was clearly altered in six patients: increased retention in the metastatic sites and less background radioactivity of the normal tissues. These findings were fully consistent with the MIBG predosing experiments in carcinoid BON xenografts in nude mice.
Based on the improved tumour exposure five patients qualified for the combined schedule of 131 I-MIBG with a non-radiolabeled MIBG predose. The results were encouraging. All patients experienced an impressive palliative effect for 11 months (range 6-12 months) similar to the previously reported group of 30 patients receiving only the radioactive 131 I-MIBG treatment [4] . The main difference with our previous series, however, is the frequent finding of biochemical response: an impressive decrease in 5-HIAA excretion was found in all of the cases, meeting the criteria of partial remission in three of the five patients compared to two of thirty (7%) without the predosing. As in the treatment of 131 I-MIBG alone side effects were still minimal and of short duration.
Octreotide is presently considered firstline treatment by many physicians based on a symptomatic improvement in 60%-80% of carcinoid patients. The hitherto major disadvantage of daily multiple injections is circumvented by two available, long acting formulations (2-4 weekly intramuscular injection) [10, 11] This resulted in a symptomatic improvement in approximately 55% accompanied by a biochemical response in 42%. The present schedule of 131 I-MIBG therapy after MIBG predosing seems to be similarly effective with the advantage of the long duration of response (approximately one year).
MIBG uptake in neuroblastoma and pheochromocytoma proceeds via an active 'uptake-I' system on the plasma membrane [2, 12, 13] . In carcinoids no experimental evidence exist for such a mechanism [14] . Blood platelets resemble carcinoid cells because both have large serotonin-storing capacities. Platelets selectively accumulate MIBG via the serotonin transport system, concluded from selective inhibitor profiles and mutual substrate inhibition of 125 I-MIBG uptake in vitro [15] . Our preliminary studies with carcinoid BON cells cultured in vitro, indicate that their accumulation of MIBG clearly differs from that in platelets, being much slower and not inhibited by an excess serotonin. Using selective (re)uptake inhibitors of either serotonin or norepinephrine [15, 16] and supported by analyses of various transporters at the RNA level [17] carcinoid BON tumour cells appearently lack specific plasma membrane transporters for these bioamines. Moreover, carcinoids are known to take up amino-acid precursors for the endogenous production of serotonin which does not require a serotonin transporter as recently shown by Orlefors [18] . It has been reported that MIBG does concentrate in the absence of an active transport system [19] . We hypothesize that efficient storage in the neuroendocrine granules, apparently following nonspecific cellular uptake, is the major mechanism of net MIBG accumulation. This is supported by the recent findings in gastric carcinoid tumours of which five out of six express vesicular monoamine transporter type 2 [20] . With regard to altered normal tissue distribution this phenomenon might be explained by MIBG being higly protonated at physiological pH [13] . It is a typical organic cation and will likely stick to biological tissues [12, 13] . Hence, partial blocking of these non-specific binding sites by excess non-radiolabeled MIBG may reduce subsequent binding of radiolabeled MIBG. Another plausible reason to explain the lower levels of radiolabeled MIBG in normal tissues after predosing, is the systemic sympathomimetic effects due to induced release of norepinephrine [13, 21] . MIBG can displace catecholamines from their natural tissue stores resulting in the clinical finding of changes in blood pressure and tissue perfusion during MIBG infusion [4] ; induction of local haemodynamic effects have also been reported in mice [12] . Tumour vessels are not innervated and therefore these changes in bioactive amine levels induced by an excess of MIBG, presumably have different effects on the biodistribution of radioactive MIBG in tumour and normal tissues [12, 13, 21] .
In conclusion, predosing with non-radiolabeled MIBG simply and effectively improves I31 I-MIBG tumour targeting and enhances its therapeutic effect in patients with symptomatic, metastatic carcinoid.
